Mylan revenues up 12% in Q1
The company has reported net earnings of $104.55m, compared to $94.27m for the same period prior year. For the first quarter of 2011, Mylan‘s earnings from operations was
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.